Article
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
7 Aug 2017
Abstract excerpt
Signal transducer and activator of transcription 3(STAT3) is an emerging target for cancer therapy. In this study, we identify Toosendanin (TSN) is an effective inhibitor of STAT3, leading to the impediment of various oncogenic processes in osteosarcoma. TSN selectively inactivates phospho-STAT3 (Tyr-705); subsequent molecular docking and in vitro SPR analysis uncover TSN directly binds to the SH2 domain of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
